BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10

Reuters · 03/16/2021 21:04
BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10

- Arcus Biosciences Inc RCUS.N:

  • ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY

  • ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION

  • ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION

Source text: (https://bit.ly/3rTSkBd)

Further company coverage: RCUS.N


((Reuters.Briefs@thomsonreuters.com;))